lenalidomide has been researched along with EBV Infections in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, H; Honda, A; Imadome, KI; Iwasaki, A; Jona, M; Kishino, Y; Kurokawa, M; Maki, H; Morita, K; Nishikawa, M; Ushiku, T; Yatomi, Y; Yoshida, M | 1 |
| Chen, L; Cui, T; He, X; Meng, G; Song, D; Song, Y; Wang, J; Wang, X; Wang, Y; Wang, Z; Wu, L; Yin, Q; You, Y | 1 |
| Au-Yeung, R; Chan, TSY; Ip, AHW; Kwong, YL; Pang, AWK | 1 |
| Chan, TSY; Kwong, YL; Mak, V | 1 |
| Au-Yeung, R; Hwang, YY; Kwong, YL; Lau, HP | 1 |
| Arima, N; Fukunaga, A; Kishimoto, W; Kitano, T; Matsuzaki, N; Nakae, Y; Tabata, S; Takiuchi, Y; Yuba, Y | 1 |
| Degen, L; Juskevicius, D; Läubli, H; Rochlitz, C; Stenner-Liewen, F; Tzankov, A | 1 |
| Baladandayuthapani, V; Dawson, CW; Iempridee, T; Jones, RJ; Kenney, SC; Lee, HC; Lin, HC; Mertz, JE; Orlowski, RZ; Shah, JJ; Wang, X; Weber, DM | 1 |
| DeLaune, J; Grosbach, A; Norkin, M; Schmit, JM | 1 |
| Chim, CS; Choi, PT; Lee, WK | 1 |
10 other study(ies) available for lenalidomide and EBV Infections
| Article | Year |
|---|---|
Development of Epstein-Barr virus-associated lymphoproliferative disorder and hemophagocytic lymphohistiocytosis during long-term lenalidomide maintenance therapy in multiple myeloma.
Topics: Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Immunomodulating Agents; Lenalidomide; Lymphohistiocytosis, Hemophagocytic; Lymphoproliferative Disorders; Multiple Myeloma | 2023 |
PD-1 blockade and lenalidomide combination therapy for chronic active Epstein-Barr virus infection.
Topics: Adolescent; Chronic Disease; DNA Copy Number Variations; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Lenalidomide; Leukocytes, Mononuclear; Programmed Cell Death 1 Receptor; Prospective Studies | 2023 |
Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Etoposide; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell; Male; Neoplasms, Second Primary; Positron Emission Tomography Computed Tomography; Prednisolone; Vincristine | 2020 |
Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide.
Topics: Aged, 80 and over; DNA, Viral; Drug Eruptions; Drug Monitoring; Eosinophilia; Epstein-Barr Virus Infections; Gastrointestinal Stromal Tumors; Herpesvirus 4, Human; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Primary Effusion; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiography, Thoracic; Treatment Outcome; Tumor Burden | 2017 |
Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide.
Topics: Aged, 80 and over; Aging; Antigens, CD; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lenalidomide; Lymph Nodes; Lymphoproliferative Disorders; Male; Plasma Cells; Positron Emission Tomography Computed Tomography; Thalidomide | 2018 |
A case of AITL complicated by EBV-positive B cell and monoclonal plasma cell proliferation and effectively treated with lenalidomide.
Topics: Aged, 80 and over; Cell Proliferation; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Lenalidomide; Lymphoma, T-Cell, Peripheral; Plasma Cells | 2019 |
Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder.
Topics: Adult; B-Lymphocytes; Biopsy; Epstein-Barr Virus Infections; Female; Genomics; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; Lenalidomide; Lymphoproliferative Disorders; Remission Induction; Thalidomide; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.
Topics: Animals; Cell Line, Tumor; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Thalidomide; Virus Activation; Virus Latency | 2016 |
A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Computed Tomography Angiography; Cyclophosphamide; Dexamethasone; Epstein-Barr Virus Infections; HIV Seronegativity; Humans; Lenalidomide; Male; Plasmablastic Lymphoma; Prognosis; Remission Induction; Sigmoid Neoplasms; Thalidomide | 2017 |
Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Boronic Acids; Bortezomib; Combined Modality Therapy; Dacarbazine; Dexamethasone; Doxorubicin; Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasms, Second Primary; Pyrazines; Salvage Therapy; Thalidomide; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vincristine | 2013 |